Cetuximab & Panitumumab
Erbitux · Vectibix · Anti-EGFR antibody
TRPM6 magnesium wasting.
LYTE
MildOpen →
Anti-RANKL antibody
Denosumab
Xgeva · Dmab
An anti-RANKL antibody that is renally safe but can trigger dangerous hypocalcemia in low GFR.
ModerateAnti-RANKL monoclonal antibody · approved 2010
Bone metastases (skeletal-related events)Giant cell tumor of boneHypercalcemia of malignancy
Signature kidney injury
Electrolyte Wasting
Denosumab is not directly nephrotoxic and is not renally cleared, but the risk of severe hypocalcemia rises sharply as kidney function declines. In a population-based cohort, severe hypocalcemia occurred in 0.2% of all new users but in 14.9% of those with eGFR <15 mL/min/1.73 m2 or on dialysis (mild hypocalcemia 24.1% in that group).
Source: Cowan et al., J Bone Miner Res 2023
Mechanism of kidney injury
Profound inhibition of osteoclast-mediated bone resorption blocks the calcium efflux from bone needed to defend serum calcium. In advanced CKD, impaired 1-alpha-hydroxylation (low calcitriol), hyperphosphatemia, vitamin D deficiency, and reduced calcium mobilization compound the effect, producing severe and sometimes prolonged hypocalcemia with a compensatory surge in PTH. This is an electrolyte/mineral toxicity, not parenchymal kidney injury - renal function itself is not impaired by the drug.
Clinical presentation
Hypocalcemia with paresthesias, carpopedal spasm/tetany, Chvostek/Trousseau signs, QT prolongation, and seizures in severe cases, often with hyperphosphatemia and markedly elevated PTH. Renal function (creatinine/eGFR) is typically unchanged by the drug.
Onset
Within days to a few weeks of dosing (nadir often around 1-2 weeks); can be prolonged given the drug's months-long duration of effect and the absence of a reversal agent.
Reversibility
Reversible
Anticancer mechanism
Fully human monoclonal antibody against RANKL (receptor activator of nuclear factor-kappa-B ligand) that prevents RANKL from engaging its receptor RANK on osteoclast precursors, inhibiting osteoclast formation, function, and survival and thereby suppressing bone resorption. Used to prevent skeletal-related events in bone metastases, for giant cell tumor of bone, and for hypercalcemia of malignancy.
Management
Aggressive calcium and active vitamin D (calcitriol) repletion - oral and IV calcium for symptomatic/severe hypocalcemia; monitor and correct magnesium and phosphate; in dialysis patients adjust the calcium dialysate concentration. Hold further denosumab until calcium normalizes; effect persists for months, so prolonged supplementation may be needed.
Risk factors
- Advanced CKD / dialysis (eGFR <30, and especially <15 mL/min/1.73 m2)
- Vitamin D deficiency and low baseline serum calcium
- High bone-turnover states or extensive osteoblastic metastases (hungry-bone physiology)
- Hypomagnesemia impairing PTH action
Prevention
- Measure and correct serum calcium, vitamin D, and magnesium before dosing
- Co-prescribe calcium and active vitamin D (calcitriol), with higher doses in CKD
- Monitor calcium closely after each dose, especially with eGFR <30 mL/min, and individualize the decision to dose in ESKD
Note · Severe hypocalcemia in low GFR is the key hazard; denosumab is not directly nephrotoxic and is not renally cleared. classId 'anti_rankl' denotes the anti-RANKL antibody class.
Clinical depth
Renal dose adjustment
No dose reduction for renal function (cleared by the reticuloendothelial system, independent of GFR), but in CKD stage 4-5/dialysis the hazard is hypocalcemia - intensify calcium/vitamin D and monitoring rather than altering the dose. Avoid concurrent same-indication dosing of Xgeva and Prolia.
Dialyzability & ESKD dosing
Monoclonal antibody (IgG2); not dialyzable and pharmacokinetics are unaffected by dialysis. Hemodialysis is used to manage the metabolic consequences, not to remove the drug.
Differential diagnosis
Denosumab hypocalcemia (suppressed bone resorption, high PTH, recent dose) vs CKD-MBD hypocalcemia vs hungry-bone syndrome post-parathyroidectomy vs hypomagnesemia-related hypocalcemia. Note this is an electrolyte toxicity - the drug does not cause AKI, distinguishing it from nephrotoxic antiresorptives like IV bisphosphonates (which can cause ATN/collapsing FSGS).
Monitoring
- Serum calcium before every dose and within 1-2 weeks after, especially in CKD/dialysis
- 25-OH vitamin D, magnesium, and phosphate
- PTH in advanced CKD
- ECG/QTc and symptoms if hypocalcemia is severe
Key trials & series
- Cowan J Bone Miner Res 2023 ICES population-based cohort (hypocalcemia by eGFR)
- Pivotal SRE-prevention trials in bone metastases (e.g. denosumab vs zoledronic acid programs)
Clinical pearls
- Unlike bisphosphonates, denosumab is not nephrotoxic and needs no renal dose change - the danger in low GFR is hypocalcemia.
- Check and replete calcium, vitamin D, and magnesium before dosing, and recheck calcium within 1-2 weeks in CKD/dialysis.
- There is no reversal agent and the effect lasts months, so denosumab-induced hypocalcemia can be severe and prolonged - dialysis patients are highest risk.
Where it strikes
Nephron segments
Distal Tubule / Collecting Duct
Fine-tuning of Na, K, Mg, acid & water
Injury signatures
Electrolyte Wasting
Beyond the kidney
Class-level context for the major non-renal toxicities of anti-rankl antibodys.
Musculoskeletal
Myalgia, myositis, rhabdomyolysis, ONJ
- Osteonecrosis of the jaw, hypocalcemia, acute-phase reaction
Evidence
5 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkHypocalcemia Risk of Denosumab Across the Spectrum of Kidney Disease: A Population-Based Cohort Study.Cowan A et al. · J Bone Miner Res 2023 · PMID 36970786Quantifies steeply rising hypocalcemia risk with worsening kidney function (14.9% severe at eGFR <15 or dialysis).PMIDDenosumab in chronic kidney disease: a narrative review of treatment efficacy and safety.Gopaul A et al. · Arch Osteoporos 2021 · PMID 34319515Reviews denosumab safety in CKD, emphasizing hypocalcemia management and the lack of direct nephrotoxicity.PMIDSevere Hypocalcemia and Dramatic Increase in Parathyroid Hormone after Denosumab in a Dialysis Patient: A Case Report and Review of the Literature.Bhanot RD et al. · Case Rep Nephrol 2019 · PMID 31016056Illustrative dialysis case of severe symptomatic hypocalcemia with PTH surge, managed by calcium repletion and dialysate adjustment.PMIDSafety of denosumab in patients with chronic kidney disease.Al Adhoubi NK et al. · Saudi J Kidney Dis Transpl 2021 · PMID 35532692Observational data noting no deterioration in renal function but hypocalcemia risk in advanced CKD.PMIDOnconephrology: The intersections between the kidney and cancer.Rosner MH et al. · CA Cancer J Clin 2020 · PMID 32853404Onconephrology review covering bone-targeted therapies and electrolyte disorders in cancer.